Scopus Enriches Literature Research with PatentCites and WebCites Features
New citation features provide additional insights into influence of research
Amsterdam – September 28, 2006 – Scopus®, the world’s largest abstract and citation database of research information and quality Web sources, today announced the launch of two new features. PatentCites, released to customers on September 22nd, allows users to track how primary research is practically applied in patents. WebCites, which is to be launched shortly, is the first step towards enabling Scopus users to track the influence of peer reviewed research on web literature.
Researchers want to know the influence of research described in a published journal article. Influence can be evaluated by how often an article has been cited in other research articles; however, research influence often extends beyond the official scholarly literature. For example, how the article has been used in patents, theses or other “grey literature” often available on the web.
Scopus PatentCites clearly identifies citations from patent sources that cite Scopus articles on the Abstract and References page. Just like article citation counts, PatentCites links directly to the source items. This unique feature enables users to immediately see the relationship of primary research to its practical application in patents and will be of particular value to those working in disciplines such medicine, engineering, chemistry, agriculture or other applied sciences.
Among the key growing number of patent sources covered and updated daily are the US Patent Office, European Patent Office and the World Intellectual Property Organization.
In the forthcoming release of WebCites, users will be able to view citations to articles in Scopus from a growing number of carefully selected scientific web sources such as Institutional Repositories and Thesis and Dissertation databases as well as other carefully selected web sources. Users will be able to gain additional insights into the influence of specific articles and place article citation numbers from outside the peer-reviewed realm into perspective.
Like PatentCites, WebCites will be presented clearly in a separate display allowing the user to link directly to the relevant source items through just one click.
“Scopus users already enjoy full integration of the scientific Web in the search results. We have further applied the fundamental strengths of Scopus – namely the selection of quality and relevant sources, and powerful citation tracking –” says Scopus Director, Jaco Zijlstra “to disclose the influence of peer reviewed research literature on online grey literature and patents“.
Covering the world’s research literature, Scopus is the largest and easiest to use navigation tool ever built. Scopus is designed and developed with over 300 users and librarians internationally. Its unique database contains abstracts and references from over 15,000 titles from 4,000 different publishers, ensuring broad interdisciplinary coverage. In addition, Scopus not only offers users citation information about the articles covered, but also integrates web & patent searches directly from its clean and simple interface. Direct links to full-text articles, library resources and other applications like reference management software, make Scopus quicker, easier and more comprehensive to use than any other literature research tool.
For more information about Scopus please visit www.info.scopus.com. About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Fusion Public Relations
T: +1 202 898 2000